Oncology pharmacy Onco360 stated on Friday that it will market TAZVERIK (Tazemetostat) for treatment of patients with epithelioid sarcoma under the exclusive specialty pharmacy partnership with Epizyme.
Epizyme added that TAZVERIK (Tazemetostat) is a FDA approved new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Epithelioid sarcoma is a rare, slow-growing subtype of soft tissue sarcoma which occurs primarily in young adults. Greater than 90% of epithelioid sarcoma patients are found to have a genetic mutation, known as loss of INI-1 function, rendering them amenable to treatment with TAZVERIK, a novel EZH2 inhibitor.
In conjunction, TAZVERIK is manufactured by Epizyme, a research-based biotechnology company.
US FDA approval of TAZVERIK is based on the results from Epizyme's open-label, single-arm cohort of patients from the Phase II EZH-202 clinical trial (NCT02601950), which demonstrated a 15% overall rate of response.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients